Registered business · FR · Founded 2007 · Accounts through 2024 · Updated Jul 27, 2026
Public range today€5m - €14m
See what is holding the value back today, what this company could be worth in five years and which actions make the difference. The estimate is based on filed annual accounts.
Is this your company? Claim and manage this profile
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accountsThe historical valuation curve is public. Create a free account for the future five-year growth forecast, the insights behind it, and concrete action points that can increase this company’s value.
Free account · private workspace
Public filings are a starting point. Owner-confirmed accounts, net debt, leases and commercial context can refine the range for a sale, financing or transfer.
You have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
Indicative public valuation range based on financial year 2024. This historical record does not yet contain an immutable calculation snapshot, so no sector range is reconstructed after the fact. Not a transaction value, asking price or fairness opinion.
Register your interest privately. Upswitch reviews every request and keeps it queued until a safe, verified owner contact route is available.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Claim this companyPROVEPHARM is a business in NACE sector 71.20 based in France. The company was founded in 2007.
PROVEPHARM is listed in French National Business Register (RNE/INPI) under registry number 500620489. The public employee band is 12, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Within the French NACE 71.20 cluster, public-record data is filed annually via the national company registry.
Across the 2017-2024 window revenue has declined, moving from €30,420,241 to €15,019,511.
A public indicative value curve is available for PROVEPHARM, based on filed company accounts. A free account unlocks the five-year outlook and concrete actions to increase value.
The most recent annual filing covers 2024 (period end 2024-12-31).
If you are researching PROVEPHARM for acquisition, investment, or due-diligence purposes, this page consolidates its firmographics, multi-year filings, and an indicative valuation into a single, citation-ready view.
Public regulator-filed figures across 8 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202431 Dec 2024 | €15,019,511 | - | €103,829,450 | €11,184,478 | - |
| 202331 Dec 2023 | €63,603,396 | - | €143,613,707 | €58,669,165 | - |
| 202231 Dec 2022 | €79,855,494 | - | €102,746,298 | €52,391,620 | - |
| 202131 Dec 2021 | €57,013,925 | - | €90,036,869 |
PROVEPHARM was founded in 2007 and is registered with French National Business Register (RNE/INPI).
PROVEPHARM is registered under NACE 71.20. That places the business within the French cluster for this activity.
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for PROVEPHARM may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
| €36,667,873 |
| - |
| 202031 Dec 2020 | €42,636,126 | - | €74,720,262 | €30,028,193 | - |
| 201931 Dec 2019 | €39,019,906 | - | €45,500,096 | €24,798,202 | - |
| 201831 Dec 2018 | €29,420,349 | - | €40,242,258 | €22,051,912 | - |
| 201731 Dec 2017 | €30,420,241 | - | €33,503,169 | €15,180,707 | - |
The most recently filed annual accounts cover fiscal year 2024 (period end 2024-12-31), publicly available via French National Business Register (RNE/INPI).
